Skip to content

Aurinia Pharmaceuticals AUPH Other Commercial Liabilities

Other Commercial Liabilities at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's other commercial liabilities?
Aurinia Pharmaceuticals (AUPH) reported other commercial liabilities of $58.2M in Q1 2026.
How has Aurinia Pharmaceuticals's other commercial liabilities changed year-over-year?
Aurinia Pharmaceuticals's other commercial liabilities increased by 37.4% year-over-year, from $42.35M to $58.2M.
What is the long-term trend for Aurinia Pharmaceuticals's other commercial liabilities?
Over 2 years (2023 to 2025), Aurinia Pharmaceuticals's other commercial liabilities has grown at a 15.4% compound annual growth rate (CAGR), from $50.06M to $66.62M.